Viatris Inc is a global healthcare company that focuses on providing access to medicines, including generic and specialty pharmaceuticals, to improve patient health outcomes worldwide
Formed from the merger of Mylan and Upjohn, a division of Pfizer, Viatris leverages its extensive portfolio to develop and manufacture a wide range of high-quality medications that address diverse therapeutic areas. With a commitment to sustainability and innovation, the company emphasizes collaboration with healthcare providers, policymakers, and communities to enhance the accessibility and affordability of essential healthcare solutions for patients around the globe.
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viatris Inc. (NASDAQVTRS) on behalf of long-term stockholders following a class action complaint that was filed against Viatris on May 15, 2023 with a Class Period from March 1, 2021 and February 25, 2022. Our investigation concerns whether the board of directors of Viatris have breached their fiduciary duties to the company.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viatris Inc. (NASDAQVTRS) on behalf of long-term stockholders following a class action complaint that was filed against Viatris on May 15, 2023 with a Class Period from March 1, 2021 and February 25, 2022. Our investigation concerns whether the board of directors of Viatris have breached their fiduciary duties to the company.
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 14, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Viatris Inc. (“Viatris” or the “Company”) (NASDAQVTRS) common stock between March 1, 2021 and February 25, 2022, inclusive (the “Class Period”).
Did you lose money on investments in Viatris? If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
Did you lose money on investments in Viatris? If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
Did you lose money on investments in Viatris? If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
NEW YORK, June 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQVTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the “Class Period”), of the important July 14, 2023 lead plaintiff deadline.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Western District of Pennsylvania on behalf of those who acquired Viatris, Inc. (“Viatris” or the “Company”) (NASDAQVTRS) securities during the period from March 1, 2021 through February 25, 2022 (the “Class Period”). Investors have until July 14, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
